NOVARTIS AG

Novartis shares dip 1.05% on Nov 26, staying above its 200‑day MA yet below the 52‑week high; investors track its R&D pipeline, market dynamics, and Swiss health‑sector trends.

Novartis shares rise 0.3% amid steady 8.95% monthly gain; trading near CHF 128, above 200‑day SMA, and in a tight 52‑week range—discover why investors remain cautiously bullish.

Novartis defends Swiss markets with a 1.85% rise—showing how its diversified drug pipeline and resilient earnings beat volatility and boost long‑term value.